loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Caplin Point Laboratories Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Caplin Point Laboratories Ltd. 05 Nov 2025 14:17 PM
Result PDF

Q2FY26 Quarterly Result Announced for Caplin Point Laboratories Ltd.

Pharmaceuticals company Caplin Point Laboratories announced Q2FY26 results

  • Revenue from Operation: Rs 534.0 crore compared to Rs 483.1 crore during Q2FY25, change 10.5%.
  • EBITDA: Rs 219.5 crore compared to Rs 185.5 crore during Q2FY25, change 18.3%.
  • EBITDA Margin: 38.9% for Q2FY26.
  • PBT: Rs 201.0 crore compared to Rs 168.5 crore during Q2FY25, change 19.3%.
  • PAT: Rs 160.2 crore compared to Rs 130.8 crore during Q2FY25, change 22.5%.

C.C. Paarthipan, Chairman, said: "Consistency has been the cornerstone of Caplin’s journey. We are pleased to report another strong set of results, fully aligned with our long-term growth path and guidance. Our unwavering focus on cashflows, profitability, and revenue growth continues across all segments of the business, complemented by an equally strong commitment to compliance and governance.

We are leveraging our deep understanding of smaller Latin American markets through our subsidiaries in the front end, together with our R&D and supply chain excellence at the back end, to create a powerful foundation for expansion into larger markets such as Mexico, Chile, Colombia, and eventually Brazil.

Our relentless emphasis on compliance and operational productivity continues to drive robust growth in regulated markets like the U.S. and Canada, and we expect this segment to represent an even greater share of our business in the coming years. Meanwhile, our China 2.0 strategy positions us to fast-track entry into high-potential areas such as Biosimilars and Peptides — segments traditionally dominated by larger players.

The building blocks we are putting in place from now and over the next couple of year will set Caplin on a strong, multi-year growth trajectory, underpinned by the same consistency, discipline, and performance metrics that have defined us thus far."

Result PDF

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q1FY26 results

  • Gross Margin for Q1FY26 is 61.7% vs 59.6% in Q1FY25 aided by new product launches across existing and new markets.
  • EBITDA Margin for Q1FY26 is at 37.7% vs 35.7% in Q1FY25.
  • Basic EPS increased by 23.1% to Rs 20.10 in Q1FY26 compared to Rs 16.32 in Q1FY25.
  • Cash Flow from Operations in Q1FY26 is Rs 118 crore vs Rs 96 crore in Q1FY25.
  • Free Cash Flow is Rs 53 crore (after Capex investment of Rs 65 crore) in Q1FY26 as compared to Rs 59 crore (after capex investment of Rs 37 crore) in Q1FY25.
  • Geographical revenue composition between Emerging Markets (Latin America & Africa) and US for Q1FY26 is in the range of 79% and 21% respectively.
  • CSL’s Revenue composition demonstrates a balanced mix of Product Supply and Milestone Profit Share, with the split for Q1FY26 in the range of 85% and 15% respectively.
  • As of 30th June 2025, Inventories are at Rs 324 crore - 56% Stock at the warehouses, close to the customer; In Transit 13%; 31% in India. Receivables are at 114 days.
  • As of 30th June 2025, Free Cash reserves are at Rs 1,237 crore and Total Liquid Assets at Rs 2,207 crore.

C.C. Paarthipan, Chairman, said: "We’re putting in place the right building blocks for both Emerging Markets and Regulated markets. We're making good progress with finalizing partners and also filing dossiers in our new key target markets of Mexico, Chile, USA etc. We're also aiming to gradually onshore some strategic manufacturing at important locations in Latin America and US, and taking the first steps of acquiring land/buildings for the same. We've also launched our second innings from China which will focus more deeply on high-tech products like Biosimilars, Peptides etc. We're strengthening our Marketing and Regulatory teams at both India and LatAm with seasoned professionals, to ensure our growth momentum remains steady. We continue to have a sharp focus on consolidating our presence in the existing markets with expansion on products, profits and cashflows."

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Gross Margin: 60% vs. 56.6% in Q4FY24 — aided by new product launches across existing and new markets.
  • Revenue from Operations: Rs 502.5 crore vs. Rs 453.2 crore in Q4FY24 — up 10.9% YoY.
  • EBITDA: Rs 193.8 crore vs. Rs 162.5 crore in Q4FY24 — up 19.2% YoY.
  • EBITDA Margin: 36.7% vs. 34.5% in Q4FY24
  • Profit After Tax (PAT): Rs 145.3 crore vs. Rs 121.2 crore in Q4FY24 — up 19.8% YoY.

FY25 Financial Highlights:

  • FY25 Total Revenue at Rs 2034 crore; an increase of 15.5% YoY
  • FY 25 PAT at Rs 541 crore; (Growth of 17.3% over FY24)
  • EBITDA Margin: 36.5% vs. 35.1% in FY24 
  • Basic EPS increased by 17.2% to Rs 70.57 in FY25 compared to Rs 60.19 in FY24.
  • Cash Flow from Operations in FY25 is Rs 432.39 crore vs Rs 318 crore in FY24. 
  • CSL's Total revenue crosses Rs 366 crore, an increase of 15% over FY24.
  • US Market FY25 EBIDTA crosses Rs 102 crore (Growth of 71% over FY24)
  • Free Cash Reserves at Rs 1,180 crore; Liquid Assets at Rs 2,148 crore

Commenting on the performance, C.C. Paarthipan, Chairman said: "We’re delighted to close out another year with excellent Top and Bottom Line Growth, and continue our progress on being a benchmark when it comes to Cashflows. Our front end in the US is taking shape at a good pace and we expect this entity to drive strong growth for the parent company over the next few years. We’re once again focusing on getting back to Asset Light outsourcing using our Second Innings at China, with import of Peptides and Key starting materials for Biosimilars, which we plan to file and launch in our Emerging Markets where we have a significant presence already. With our API entities coming on stream in the very near future, we can truly envision Caplin being a fully integrated global Pharma player in the years to come."

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q3FY25 results

  • Revenue: Rs 493.0 crore compared to Rs 435.5 crore during Q3FY24, change 13.2%.
  • EBITDA: Rs 193.7 crore compared to Rs 159.5 crore during Q3FY24, change 21.4%.
  • PBT: Rs 177.3 crore compared to Rs 145.4 crore during Q3FY24, change 21.9%.
  • PAT: Rs 140.1 crore compared to Rs 119.8 crore during Q3FY24, change 16.9%.
  • Gross Margin for Q3FY25 is 60.4% vs 56.3% in Q3 FY24.
  • EBITDA Margin for Q3FY25 is at 36.9% vs 35.2% in Q3 FY24.
  • As of 31st December 2024, Inventories are at Rs 333 crore - 52% Stock at the warehouses, close to the customer; In Transit 18%; 30% in India.
  • Receivables is at 118 days. As of 31st December, 2024 Free Cash reserves are at Rs 1,081 crore and Total Liquid Assets at Rs 2,042 crore.

C.C. Paarthipan, Chairman, said: We’re happy to report another strong set of numbers for this quarter, underlining our sharp focus on consistency in all areas. The company has shown encouraging progress within a very short period when it comes to the launch of our own label in the US, and with consistent on-time approvals, we’re confident that this entity will deliver robust growth to the organization. We’re making good progress in our key emerging markets of Mexico and Chile, and we can start to see tangible growth from these areas in the next couple of years. The company is well positioned for continued growth in all parameters, with benchmark cashflows for multiple years to come.

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced H1FY25 & Q2FY25 results

  • Gross Margin for Q2FY25 is 60.9% vs 60.0% in Q2FY24 and H1FY25 is 60.3% vs 57.4% in H1FY24, aided by new product launches across existing and new markets.
  • EBITDA Margin for Q2FY25 is steady at 36.8% vs 36.7% in Q2FY24 and H1FY25 is 36.3 % vs 35.4% in H1FY24.
  • Basic EPS increased by 16.6% to Rs 33.54 in H1FY25 compared to Rs 28.75 in H1FY24.
  • Cash Flow from Operations in H1FY25 is Rs 186 crore vs Rs 129 crore in H1FY24.
  • Free Cash Flow is Rs 109 crore (after Capex investment of Rs 77 crore) in H1FY25 as compared to Rs 50 crore (after capex investment of Rs 79 crore) in H1FY24.
  • Geographical revenue composition between Latin America & Rest of World and US for H1FY25 is in the range of 82% and 18% respectively.
  • CSL's revenue composition demonstrates a balanced mix of Product Supply and Milestone Profit Share, with the split for H1FY25 in the range of 75% and 25% respectively.
  • As of Q2FY25, Inventories are at Rs 327 crore - 50% Stock at the warehouses, close to the customer; In Transit 20%; 30% in India.
  • Receivables is at 118 days.
  • As of Q2FY25 Free Cash reserves are at Rs 1,039 crore and Total Liquid Assets at Rs 1,984 crore.

C.C. Paarthipan, Chairman, Caplin Point Laboratories, said: Consistency and Stability are key factors in the sustainability of any business. When we add our unique business model of taking the road less travelled and catering to the bottom of the pyramid, you have a potent combination. Our relentless focus towards high degree of compliance, supply chain efficiency and robustness in cashflows has led to another strong quarter, driven both by our Emerging Markets business in LatAm and our growing business in the US. We remain confident of keeping up these fundamentals in the years to come.

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q1FY25 results:

  • Gross Margin for Q1FY25 is 59.6% vs 55.3% in Q1FY24.
  • EBITDA Margin for Q1FY25 is 35.7% vs 34.0% in Q1FY24, aided by new product launches.
  • Basic EPS increased by 19.8% to Rs 16.32 in Q1FY25 compared to Rs 13.62 in Q1FY24.
  • Cash Flow from Operations in Q1FY25 is Rs 96 crore (EBITDA to Cashflow conversion of 56.4%).
  • Free Cash Flow is Rs 59 crore (after Capex investment of Rs 37 Crores) in Q1FY25 as compared to Rs 37 crore (after capex investment of Rs 51 Crores) in Q1FY24.
  • Geographical revenues: Latin America and Rest of World 83%, US 17%.
  • Caplin Steriles Ltd (“CSL”) Q1FY25 Operating Revenue is at Rs 77.93 crore, with 68.9% Y-o-Y growth.
  • CSL's revenue composition demonstrates a balanced mix of Product Supply and Milestone Profit Share, with the split for Q1FY25 in the range of 74% and 26% respectively.
  • As of 30th June 2024, Inventories are at Rs 311.60 crore, Receivables is at 113 days.
  • Free Cash Reserves are at Rs 969.2 crore. Total Liquid Assets of the Company (Inventory Receivables Free Cash Reserves) are at Rs 1,849 crore as on 30th June’ 2024

Commenting on the performance, C.C. Paarthipan, Chairman said: Our company continues to be an outlier, whether its taking the road less travelled in Latin America, or focusing on our Cashflow and Bottom line rather than unsustainable or inconsistent top line growth. We’re pleased to report yet another strong set of numbers for this quarter. LatAm is a key driver of growth but we’re now also supported by strong performance from the US. As we embark on launching our own frontend in the US, we remain confident that our pattern of success through taking the road less travelled would repeat itself in the biggest markets in the world as well.

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q3FY24 & 9MFY24 results:

Consolidated Q3FY24:

  • Revenue from Operation: Rs 435.50 crore, increased by 17.0% compared to Q3FY23.
  • Total Revenue: Rs 452.68 crore, increased by 17.2% compared to Q3FY23.
  • Gross Profit: Rs 245.39 crore, increased by 17.9% compared to Q3FY23.
  • Gross Margin%: 56.3%, increased from 55.9% in Q3FY23.
  • EBITDA: Rs 159.46 crore, increased by 29.1% compared to Q3FY23.
  • EBITDA Margin%: 35.2%, increased from 32.0% in Q3FY23.
  • PBT: Rs 145.41 crore, increased by 30.1% compared to Q3FY23.
  • PBT Margin%: 32.1%, increased from 28.9% in Q3FY23.
  • PAT: Rs 119.82 crore, increased by 23.0% compared to Q3FY23.
  • PAT Margin%: 26.5%, increased from 25.2% in Q3FY23.

Consolidated 9MFY24:

  • Revenue from Operation: Rs 1,240.88 crore, increased by 15.2% compared to 9MFY23.
  • Total Revenue: Rs 1,290.53 crore, increased by 15.0% compared to 9MFY23.
  • Gross Profit: Rs 708.07 crore, increased by 19.8% compared to 9MFY23.
  • Gross Margin%: 57.1%, increased from 54.8% in 9MFY23.
  • EBITDA: Rs 455.86 crore, increased by 26.0% compared to 9MFY23.
  • EBITDA Margin%: 35.3%, increased from 32.2% in 9MFY23.
  • PBT: Rs 418.40 crore, increased by 27.8% compared to 9MFY23.
  • PBT Margin%: 32.4%, increased from 29.2% in 9MFY23.
  • PAT: Rs 340.19 crore, increased by 23.4% compared to 9MFY23.
  • PAT Margin%: 26.4%, increased from 24.6% in 9MFY23.

Commenting on the performance, C.C. Paarthipan, Chairman said: "Consistency has always been a key area for our company and this Quarter is no different. The company delivered strong results, reporting Revenue from Operations of Rs 436 crore, resulting in a 17% YoY growth. Net Profit amounted to Rs 120 crore, reflecting a 23% YoY growth, with margins at 27%. Approval from Colombia’s INVIMA for our Caplin Steriles site will accelerate growth in newer markets like Mexico, Chile and Colombia, reinforcing our commitment to high regulatory standards and positioning us for success. We remain committed to driving sustainable growth with strong cashflows".

 

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q1FY24 results:

  • Revenue for Q1FY24 grew by 13.1% YoY to Rs 407 crore
  • Gross margin for Q1FY24 is at 54.8%
  • EBITDA for Q1FY24 is Rs 139 crore; EBITDA margins at 34.0%
  • Q1FY24 PAT is at Rs 104 crore up 20.8% YoY
  • Cash and cash equivalents at Rs 808 crore as of June 30, 2023
  • Cash flow from operations at Rs 88 crore for Q1FY24; Capex for Q1FY24 is at Rs 51 crore; Free cash flow for the period was Rs 37 crore
  • Basic EPS grew by 21% to Rs 13.62 in Q1FY24 against Rs 11.21 in Q1FY23
  • Receivable stood at 97 days
  • Geographical breakup of sales: LATAM & ROW 88%, US 12%

Commenting on the performance, C.C. Paarthipan, Chairman, said, “We are particularly pleased with the robust growth in our Latin America business, both in terms of revenue and profitability which also resulted in robust margins. The expansion of Softgel capacity at our CP-1 site has strengthened our position in this market, with a quick payback.

Coming to the US, with a strong order book, we are optimistic about achieving 40-50% revenue growth in FY24. We aim to achieve this growth through strategic new product launches and by increasing our market share for existing products.

Overall, we remain committed to driving sustainable growth and delivering value to all our stakeholders.”

 

 

Result PDF

Pharmaceuticals company Caplin Point Laboratories announced Q4FY23 & FY23 results:

  • Total Revenue for FY23 grew by 16.4% YoY to Rs 1,523 crore
  • Gross Margin for FY23 is at 54.8%
  • EBITDA for FY23 is Rs 497 crore with EBITDA margins at 32.6%
  • FY23 PAT is at Rs 377 crore up 22.2% YoY
  • Cash and Cash equivalents at Rs 772 crore as of 31st March 2023; Capex for FY23 is at Rs 194 crore.; Free cash flow for the period is Rs 78 crore
  • Receivables stood at 97 days as of 31st March 2023
  • Company finishes FY23 with strong top-line and bottom-line growth, supported by benchmark cashflows
  • Caplin Steriles (US Injectable business) Total Revenue crosses Rs 213 crore in FY23 with 67% YoY growth; achieving PAT breakeven
  • Capex projects of Caplin Steriles Phase 2, Caplin Onco and API unit at Vizag nearing completion
  • Company’s liquid assets (Cash, inventory & receivables) are in excess of Rs 1,450 crore
  • Q4FY23 Revenue at Rs 400.68 crore, up 14.2 % YoY, as compared to Rs 350.75 crore in Q4FY22
  • PAT for the quarter is at Rs 101.24 crore up 25.2% as compared to Rs 80.83 crore in Q4FY22
  • Basic EPS grew by 25% to Rs 49.62 in FY23 against Rs 39.61 in FY22

 

 

Result PDF

Caplin Point Laboratories announced Q3FY23 results:

  • Consolidated Q3FY23 & 9MFY23:
    • Q3FY23 revenue at Rs 386 crore, up 15.0% YoY, as compared to Rs 336 crore in Q3FY22
    • PAT for the quarter is at Rs 97 crore, up 22.8% as compared to Rs 79 crore in Q3FY22
    • PAT increased by 21.1% to Rs 276 crore in 9MFY23, against Rs 228 crore in 9MFY22
    • Cash flow from operations at Rs 176 crore for 9MFY23 
    • Basic EPS grew by 24% to Rs 36.17 in 9MFY23 against Rs 29.18 in 9MFY22 (not annualized)
    • With the depreciation of INR against USD, exchange gain in 9MFY23 is Rs 13.16 crore vs Rs 8.24 crore in 9MFY22
    • Enhanced deployment of cash has yielded an interest income of Rs 26 crore in 9MFY23 vs Rs.16 crore in 9MFY22
    • Considering the extended transit time and with a focus on the need to keep Inventory closer to customers, the current level of inventory is likely to continue in Q4 as well
    • Geographical breakup of sales: LATAM & ROW: 86%, US: 14%
  • Consolidated 9MFY23:
    • Revenue for 9MFY23 grew by 17.2% YoY to Rs 1,122 crore
    • Gross margins for 9MFY23 are at 54.8%
    • EBITDA for 9MFY23 is Rs 362 crore; EBITDA margin at 32.2%
    • 9MFY23 PAT is at Rs 276 crore, up 21.1% YoY
    • Cash and cash equivalents at Rs 718 crore. Capex for 9MFY23 is at Rs 154 crore. Free cash flow for the period was Rs 22 crore
    • Receivable stood stable around 100 days as of 9MFY23

Result PDF

Trending News

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Published on 17-Dec-2025 09:01

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL).

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL)

Published on 17-Dec-2025 09:00

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Published on 16-Dec-2025 09:05

KIMS has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Krishna Institute of Medical Sciences (KIMS) has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Published on 16-Dec-2025 09:03

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding 

Published on 16-Dec-2025 09:01

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Published on 16-Dec-2025 09:00

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status